Latest news with #SunLi
Business Wire
27-05-2025
- Business
- Business Wire
Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer
SHANGHAI, China & XIAMEN, China & ALBANY, N.Y.--(BUSINESS WIRE)-- Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced that it has entered into an option agreement with Amoytop. The two parties will engage in clinical collaboration with Drug Farm's first-in-class ALPK1 agonist, DF-006 in the field of hepatitis B and hepatocellular cancer in the Greater China region (Mainland China, Taiwan region, Hong Kong, and Macau). DF-006 is an orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver 1. DF-006 has successfully completed single and multiple ascending dose (MAD) evaluation in healthy volunteers, and MAD evaluation in virologically suppressed HBeAg negative chronic hepatitis B (CHB) patients where encouraging anti-HBV activity was observed 2. Dr. Tony, Xu, COO, Drug Farm, said:"DF-006 has a novel mechanism of action that is uniquely able to stimulate innate immunity in the liver to fight hepatitis B infection and hepatocellular cancer. In preclinical studies, DF-006 has shown enhanced efficacy against hepatitis B when combined with interferon-alpha. We look forward to assessing the clinical combination of DF-006 and Amoytop's approved drug, PEGBING ® as a potential new therapeutic regimen that may improve functional cure in hepatitis B patients.' Mr. Sun Li, Chairman and Chief Executive Officer of Amoytop, said: "Amoytop is dedicated to becoming the leading company developing a functional cure for CHB. PEGBING ® -based therapy has already demonstrated significant enhancement of functional cure rates across diverse HBV-infected populations. Through investigational research of a novel, innovative drug DF-006, we offer the potential for sustained functional cure with significant reduction of risk for hepatocellular cancer.' About Drug Farm Drug Farm is a private biotechnology Company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: Reference: Gane, EJ, et al. Journal of Hepatology, Vol. 80, Supplement 1, S87, LBP-020, June 2024 About Xiamen Amoytop Biotech Co., Ltd. Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy.
Yahoo
27-05-2025
- Business
- Yahoo
Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer
Drug Farm enters into clinical collaboration with Amoytop SHANGHAI, China & XIAMEN, China & ALBANY, N.Y., May 27, 2025--(BUSINESS WIRE)--Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced that it has entered into an option agreement with Amoytop. The two parties will engage in clinical collaboration with Drug Farm's first-in-class ALPK1 agonist, DF-006 in the field of hepatitis B and hepatocellular cancer in the Greater China region (Mainland China, Taiwan region, Hong Kong, and Macau). DF-006 is an orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver1. DF-006 has successfully completed single and multiple ascending dose (MAD) evaluation in healthy volunteers, and MAD evaluation in virologically suppressed HBeAg negative chronic hepatitis B (CHB) patients where encouraging anti-HBV activity was observed2. Dr. Tony, Xu, COO, Drug Farm, said: "DF-006 has a novel mechanism of action that is uniquely able to stimulate innate immunity in the liver to fight hepatitis B infection and hepatocellular cancer. In preclinical studies, DF-006 has shown enhanced efficacy against hepatitis B when combined with interferon-alpha. We look forward to assessing the clinical combination of DF-006 and Amoytop's approved drug, PEGBING® as a potential new therapeutic regimen that may improve functional cure in hepatitis B patients." Mr. Sun Li, Chairman and Chief Executive Officer of Amoytop, said: "Amoytop is dedicated to becoming the leading company developing a functional cure for CHB. PEGBING®-based therapy has already demonstrated significant enhancement of functional cure rates across diverse HBV-infected populations. Through investigational research of a novel, innovative drug DF-006, we offer the potential for sustained functional cure with significant reduction of risk for hepatocellular cancer." About Drug Farm Drug Farm is a private biotechnology Company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: Reference: Xu C, et al. Hepatology. 2023 Jan 1;77(1):275-289. doi: 10.1002/hep.32614. Epub 2022 Sep 17. Gane, EJ, et al. Journal of Hepatology, Vol. 80, Supplement 1, S87, LBP-020, June 2024 About Xiamen Amoytop Biotech Co., Ltd. Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. View source version on Contacts United States:Henri Lichenstein, Executive OfficerEmail: hlichens@ China:Tony Xu, and Chief Operating OfficerEmail: amoytop@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Entertainment
- Yahoo
Sun Li warns fans against AI-generated ads
20 May - Sun Li recently took to social media to warn fans to not fall victim to AI-generated ads misusing her likeness and voice. On 18 May, the actress reposted a disclaimer made by her studio, which also came with screenshots of the video that they stamped with the word "Fake", and wrote, "I must say this three times! Don't believe it! Don't believe it! Don't believe it! It's all lies! It's all lies! It's all lies!" The statement from her studio read, "Sun Li Studio recently discovered that some Internet users have posted false advertising videos related to Ms. Sun Li on self-media platforms. These false videos use technical synthesis to create false interview videos of Ms. Sun Li's image and voice to recommend products of certain businesses." "Our studio hereby solemnly declares that all product recommendation videos posted by such self-media accounts are false information. Please do not believe them and avoid being deceived!" they added. The studio also warned any parties from posting any false information and fake ads, stressing that they will pursue legal action against those who do so. (Photo Source: On CC, SINA)
Yahoo
15-05-2025
- Entertainment
- Yahoo
Sun Li's daughter won Latin dance competition in the UK
15 May - Sun Li is one proud mama as it was revealed that daughter Xiaohua has won an international Latin dance competition in London. The news was shared by a netizen, who posted a photo of Sun Li attending the competition to support her daughter Deng Hanyi (aka Xiaohua), who reportedly bested other international dancers to win the prize. In the picture, Sun Li is wearing a light-coloured top with blue jeans and can be seen holding her mobile phone to record her daughter's dancing on stage. She was also seen taking photos of Xiaohua as the 11-year-old accepted her trophy. This is not the first time that Xiaohua has won a dance competition. The actress once revealed that Xiaohua suddenly told her that she wanted to learn dancing some time ago. While she thought that her daughter wanted to do ballet like she did, Xiaohua told her mum that she was more interested in Latin dance as her best friend was also learning the dance at school. "I have no objection, but I know nothing about Latin dance. I can't give her any advice because I don't understand it," she said. Thus, Sun Li arranged for Latin dance classes for Xiaohua and let her do it on her own. (Photo Source: Sun Li Weibo, Sin Chew)
